mspipeline

I moved PI-2301 from phase 1 to phase 2 based on this press release.

I moved Daclizumab from phase 2 to phase 3 based on this press release. The drug is still in a phase 2b trial for MS, but they are going ahead with planning for the phase 3 without waiting for the conclusion of the phase 2. I don’t know if this is because Facet Biotech is really confident in daclizumab, or if they are trying to impress investors or get some kind of milestone payment from Biogen.